- Suppliers
ADM 
Armor Pharma 
Asahi KASEI 
Ashland 
BASF 
Beneo 
Captisol 
Clariant 
Croda 
DFE Pharma 
Excipio Chemicals 
Fuji Chemical 
Gattefossé 
Gangwal 
IamFluidics 
IOI Oleo 
Ingredient Pharm 
JRS Pharma 
Kerry 
KLK Oleo 
Lipoid 
Lubrizol Life Science Health 
MAGNESIA 
MEGGLE 
Nagase Viita 
Nordic Bioproducts 
Pfanstiehl 
pharm-a-spheres 
PMC Isochem 
Seppic 
ShinEtsu 
Sigachi 
SPI Pharma 
Südzucker 
Vikram Thermo 
Zerion Pharma 
All4Nutra
- Suppliers
ADM Armor Pharma Asahi KASEI Ashland BASF Beneo Captisol Clariant Croda DFE Pharma Excipio Chemicals Fuji Chemical Gattefossé Gangwal IamFluidics IOI Oleo Ingredient Pharm JRS Pharma Kerry KLK Oleo Lipoid Lubrizol Life Science Health MAGNESIA MEGGLE Nagase Viita Nordic Bioproducts Pfanstiehl pharm-a-spheres PMC Isochem Seppic ShinEtsu Sigachi SPI Pharma Südzucker Vikram Thermo Zerion Pharma - All4Nutra
A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose
SEM image of FMXIN001 new dry powder-based formulation
Objective
To examine the pharmacokinetics and safety of FMXIN001, a new intranasal powder-based naloxone formulation, in comparison to Narcan® nasal liquid spray.
Methods
FMXIN001, was developed by blending drug microspheres with larger lactose monohydrate particles, that serve as diluent and carrier, as well as a disaggregating agent. Scanning electron microscopy and X-ray were used to characterize the formulation and in vitro deposition was investigated using a nasal cast.
We compared the pharmacokinetics and safety of FMXIN001 versus Narcan® in two clinical trials: a pilot study with 14 healthy adults and a pivotal trial in 42 healthy adults (NCT04713709). The studies were open-label, single-dose, randomized, two-period, two-treatment, two-sequence crossover studies to assess the pharmacokinetics and safety of FMXIN001 versus Narcan® nasal spray.
Results
FMXIN001 comprises naloxone microspheres (5-30 μM) and lactose particles (40–240 μM). Upon in vitro testing, naloxone deposits mainly to the middle turbinates region and the upper part of the nasal cavity of a nasal cast. In human subjects, FMXIN001 produced significantly higher exposure at the initial time points of 4, 10, and 30 min, post-administration, compared to Narcan®. Both treatments were safe and well tolerated. FMXIN001, powder-based spray, results in similar overall exposure to Narcan®, but with more rapid absorption in the first 30 min.
Conclusions
FMXIN001 is expected to have a shorter onset of action for a more effective therapeutic intervention to manage opioid overdose. Rapid administration of naloxone in cases of opioid overdose is imperative, given the alarming increase in mortality rates.
Continue reading here
About this article: Lapidot, T., Bouhajib, M., Faulknor, J. et al. A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose. Pharm Res (2022). https://doi.org/10.1007/s11095-022-03247-5
